LUTECIA: Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia

Sponsor
Bayer (Industry)
Overall Status
Completed
CT.gov ID
NCT00668109
Collaborator
(none)
614
75
2
6
8.2
1.4

Study Details

Study Description

Brief Summary

Assessment of efficacy of vardenafil in subjects with erectile dysfunction and diabetes, hypertension or hyperlipidemia

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
614 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized, Open-label, Multi-center, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil in Comparison to Tadalafil in Males With Erectile Dysfunction and a Diagnosis of Diabetes, Hypertension or Hyperlipidemia
Study Start Date :
Dec 1, 2003
Actual Primary Completion Date :
Jun 1, 2004
Actual Study Completion Date :
Jun 1, 2004

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm 1

Drug: Levitra (Vardenafil, BAY38-9456)
10 mg one hour prior to sexual intercourse

Active Comparator: Arm 2

Drug: Tadalafil
10 mg taken approximately 24 hours prior to sexual intercourse

Outcome Measures

Primary Outcome Measures

  1. Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group [4 weeks]

Secondary Outcome Measures

  1. Sexual encounter profile question 2 [4 weeks]

  2. Hardness of erection [4 weeks]

  3. Other diary based variables [4 weeks]

  4. Safety and tolerability [4 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No

Inclusion Criteria:- Age: 18 years and older- Males with erectile dysfunction- Stable heterosexual relationship- Medical history / diagnosis of diabetes mellitus and/or hypertension and/or hyperlipidemia Exclusion Criteria:- Primary hypoactive sexual desire- History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months- Nitrate use- Other exclusion criteria apply according to Summary of Product Characteristics

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bruxelles - Brussel Belgium 1070
2 Bruxelles - Brussel Belgium 1200
3 Edegem Belgium 2650
4 Roeselare Belgium 8800
5 Barranquilla Colombia
6 Bogotá Colombia
7 Medellín Colombia
8 Santa Fé de Bogotá Colombia
9 Santafe de Bogotá Colombia
10 Helsinki Finland 00100
11 Helsinki Finland 00180
12 Oulu Finland 90100
13 Freiburg Baden-Württemberg Germany 79106
14 Stuttgart Baden-Württemberg Germany 70372
15 Königsbrunn Bayern Germany 86343
16 München Bayern Germany 80333
17 München Bayern Germany 81925
18 Weiden Bayern Germany 92637
19 Marburg Hessen Germany 35039
20 Hannover Niedersachsen Germany 30625
21 Osnabrück Niedersachsen Germany 49076
22 Westerstede Niedersachsen Germany 26655
23 Mönchengladbach Nordrhein-Westfalen Germany 41061
24 Berlin Germany 13125
25 Berlin Germany 13347
26 Berlin Germany 13465
27 Hamburg Germany 20354
28 Haifa Israel 31096
29 Jerusalem Israel 91120
30 Tel Aviv Israel 64239
31 Tel Hashomer Israel 52621
32 Catania Italy 95124
33 Milano Italy 20123
34 Milano Italy 20132
35 Milano Italy 20142
36 Padova Italy 35128
37 Pavia Italy 27100
38 Perugia Italy 06126
39 Pisa Italy 56126
40 Iguala Guerrero Mexico 40000
41 Monterrey Nuevo León Mexico 66260
42 Durango Mexico 34000
43 México, D. F. Mexico 06700
44 México, D.F. Mexico 14050
45 México, D.F. Mexico 14080
46 Nijverdal Netherlands 7442 LS
47 Utrecht Netherlands 3514 AB
48 Moelv Norway 2390
49 Oslo Norway 0272
50 Sarpsborg Norway 1700
51 Trondheim Norway 7006
52 Callao Peru CALLAO 2
53 Lima Peru 33
54 Lima Peru LIMA 27
55 George Eastern Cape South Africa 6530
56 Johannesburg Gauteng South Africa 2193
57 Pretoria Gauteng South Africa 0083
58 Pietermaritzburg Kwa Zulu Natal South Africa 3200
59 Newcastle Kwa Zulu-Natal South Africa 2940
60 Durban KwaZulu Natal South Africa 4091
61 Durban KwaZulu- Natal South Africa 4000
62 Durban KwaZulu-Natal South Africa 3630
63 Cape Town Western Cape South Africa 7505
64 Cape Town Western Cape South Africa 7800
65 San Juan de Alicante Alicante Spain 03550
66 L'Hospitalet de Llobregat Barcelona Spain 08907
67 Vigo Pontevedra Spain 36211
68 A Coruña Spain 15006
69 Castellón de la Plana Spain 12004
70 Málaga Spain 29010
71 Palma de Mallorca Spain 07014
72 Zaragoza Spain 50009
73 Borås Sweden 503 32
74 Skövde Sweden 541 30
75 Stockholm Sweden 171 76

Sponsors and Collaborators

  • Bayer

Investigators

  • Study Director: Bayer Study Director, Bayer

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Bayer
ClinicalTrials.gov Identifier:
NCT00668109
Other Study ID Numbers:
  • 10893
First Posted:
Apr 28, 2008
Last Update Posted:
Dec 23, 2014
Last Verified:
Dec 1, 2014

Study Results

No Results Posted as of Dec 23, 2014